MetaCap

Aquestive Therapeutics (AQST) vs Capricor Therapeutics (CAPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 32.0% versus a loss of 39.5%. Over five years, CAPR leads with a +122.6% price change compared with -45.7% for AQST. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $434.9 million), about 1.0 times the size, while Aquestive Therapeutics is growing revenue faster (-22.6% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AQST-39.51%CAPR+32.00%
+543%+233%-77%
Nov 21, 20251 yearNov 20, 2026
AQST-42.04%CAPR+127.93%
+1012%+435%-142%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AQST versus CAPR key metrics
MetricAQSTCAPR
Share price$3.46$7.59
Market cap$434.88M$441.30M
1-day change-6.61%+0.80%
YTD return-46.44%-73.70%
1-year return-39.51%+32.00%
5-year return-45.68%+122.58%
EPS (TTM)$-0.65$-2.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.55M$0
Revenue growth (YoY)-22.61%-100.00%
Net income (latest FY)$-83.78M$-105.04M
Gross margin58.35%—
Operating margin-159.50%—
Net margin-188.09%—
52-week high$6.74$40.37
52-week low$2.93$2.96
Distance from 52-week high-48.63%-81.20%
Analyst consensusstrong_buybuy
Avg. price target upside+169.65%+259.03%
Average volume2.41M4.73M
Shares outstanding125.69M58.14M
Employees147231
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed AQST by 71.5 percentage points over the past year.
  • Aquestive Therapeutics grew revenue faster in its latest fiscal year (-22.61% vs -100.00%).

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

AQST vs CAPR FAQ

Which is bigger, Aquestive Therapeutics or Capricor Therapeutics?

Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $434.88M for Aquestive Therapeutics (AQST).

Which stock has performed better over the past year, AQST or CAPR?

CAPR returned +32.00% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.

Are Aquestive Therapeutics and Capricor Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons